SYRE Spyre Therapeutics, Inc. Common Stock Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
15:57
Jun 20
A May MD
Author argues Spyre is valued billions above the more advanced Apogee despite more biosimilar.
Author argues Spyre is valued billions above the more advanced Apogee despite more biosimilar competition, larger development costs, likely dilution and no obvious acquirer, while conceding it may still be pumped; a bearish view without a disclosed or recommended short.
SYRE Spyre Therapeutics, Inc. Common Stock Avoid — —
13:33
Jun 15
A May MD
SYRE trades at a comparable market cap to a fully post-Phase 3 competitor despite being 6-8.
SYRE trades at a comparable market cap to a fully post-Phase 3 competitor despite being 6-8 years behind in development with undifferentiated me-too pipeline assets — author implies significant overvaluation relative to clinical stage and pipeline quality.
SYRE Spyre Therapeutics, Inc. Common Stock Short — —
12:54
Jun 15
A May MD
Author calls Spyre absurdly overvalued, says its open-label Phase 2a data trails blinded.
Author calls Spyre absurdly overvalued, says its open-label Phase 2a data trails blinded benchmarks of same-mechanism drugs, and flags the press release's silence on anti-drug antibodies; a bearish view without a disclosed or recommended short.
SYRE Spyre Therapeutics, Inc. Common Stock Avoid — —
Log in to see ideas

About SYRE Investor Commentary

Across the available history and selected sources, Buzzberg tracks SYRE (Spyre Therapeutics, Inc. Common Stock) across 5 sources: 0 bullish vs 4 bearish calls from 5 authors. Historical directional balance: -9% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 45 total trade ideas tracked. Latest voices: A May MD.